tirzepatide death In patients with type 2 diabetes and atherosclerotic cardiovascular disease, was noninferior to dulaglutide with respect to major cardiovascular events. Full SURPASS-CVOT trial results: https://t.co/4BWhSd0ZCC Tirzepatide linked to People Who Stopped Taking the

The regulatory enforcement environment for compounded GLP-1 telehealth is rapidly evolving

Tirzepatide SURMOUNT-1 What 6 Percentage Points Actually Means The 5.6-to-6-percentage-point gap between the drugs translates to a meaningful real-world difference for a heavier patient

When you wake up, you're in a catabolic (breakdown) state

Earlier work from the same research group identified cost and coverage limitations as the dominant reason patients stopped in the first place

Earlier gastric studies found BPC 157 protected delicate epithelial and endothelial cells, (the cells lining your gut inside and out) shielding them from inflammation-related damage